-
Fierce Biotech2 weeks ago
GE HealthCare claims photon-counting CT clearance from FDA
The new Photonova Spectra aims to capture up to 50 times more data than some of its premium CT predecessors.
-
Fierce Biotech2 weeks ago
Medtronic, Biotronik heart hardware make strides in conduction system pacing
Medtronic and Biotronik both took steps forward this week with their pacemaker hardware designed to target newly emerging geography in the heart, for delivering electric signals...
-
Fierce Biotech2 weeks ago
Ocugen eye disease gene therapy hits ph. 2 targets but underwhelms investors
Full 12-month data from Ocugen’s phase 2 eye disease gene therapy show the therapy significantly reduces the size of lesions, though the treatment’s smaller effect compared...
-
Fierce Biotech2 weeks ago
Shionogi pays Apnimed $100M for joint venture to awaken sleep disorder dream
Shionogi has struck a deal to take full control of its sleep disorder joint venture, agreeing to pay Apnimed $100 million upfront for its partner’s half...
-
Fierce Biotech2 weeks ago
Innovent sees path to China approval after eye disease drug matches Eylea in phase 3
Innovent Biologics’ eye disease prospect has matched Bayer and Regeneron’s Eylea in a phase 3 study, teeing up filings for Chinese approval of a molecule that...
-
Fierce Biotech2 weeks ago
Gilead’s $2.2B Ouro buyout delivers autoimmune T-cell engager, new purpose for Galapagos
Gilead is paying $1.68 billion for a T-cell engager company via a front-loaded deal that could also give new meaning to its aimless partner Galapagos.
-
Fierce Biotech2 weeks ago
Aardvark halts trials of obesity candidate, putting entire pipeline on pause
The voluntary pause comes less than a month after Aardvark paused a phase 3 trial for a related asset due to cardiac concerns.
-
Fierce Biotech2 weeks ago
MRI providers keep eye on rising helium prices amid war in Iran
Qatar’s exports of natural gas and helium—the latter essential for MRI scans—were effectively halted after Iran closed the Strait of Hormuz and attacked one of the...
-
Fierce Biotech2 weeks ago
Merck hands over $20M in IBD drug target deal with Flagship’s Quotient
Looking to devise new drug targets for inflammatory bowel disease, Merck will pay Flagship Pioneering’s Quotient Therapeutics $20 million upfront for access to the biotech’s somatic...
-
Fierce Biotech2 weeks ago
Stryker continues to bring hacked systems back online after patients delay surgeries
Stryker said its manufacturing capacity is ramping up quickly as plants are brought back online as well as electronic ordering and shipping.
Terns rebuffed a higher bid before selling to Merck
